Navigation Links
Nanopills release drugs directly from the inside of cells
Date:3/16/2012

UAB researchers developed a new vehicle to release proteins with therapeutic effects. The vehicles are known as "bacteria inclusion bodies", stable insoluble nanoparticles which are found normally in recombinant bacteria. Even though these inclusion bodies traditionally have been an obstacle in the industrial production of soluble enzymes and biodrugs, they were recently recognised to have large amounts of functional proteins with direct values in industrial and biomedical applications.

The research team led by Antoni Villaverde from the Institute of Biotechnology and Biomedicine (IBB) at UAB worked in collaboration with the spanish Centro de Investigacin Biomdica en Red en Bioingeniera, Biomateriales y Nanomedicina (CIBER-BBN) to verify the value of these nanoparticles as natural "nanopills" with a strong capacity to penetrate cells and carry out biological activities. The nanopill concept represents a new and promising platform for drug administration and illustrates the yet to be explored power of microbial materials in medicine.

The researchers, in a multidisciplinary study at UAB led by Dr Esther Vzquez, packaged four proteins containing different therapeutic effects into experimental nanopills, the inclusion bodies of the bacteria Escherichia coli. They put the bacteria in contact with cell cultures of mammals under similar conditions to those found in real clinical pathologies, "sick" cells with low viability, and achieved to recover their activity.

Once the technology was licensed to Janus Developments, the tolerance of its administration in vivo was confirmed through experiments conducted by UAB researcher Ester Fernndez. The results and detailed description of the "nanopill" were published in the last issue of the journal Advanced Materials.

The multidisciplinary study included researchers from IBB, the UAB Departments of Genetics and Microbiology and of Cell Biology, Physiology and Immunology, the CIBER-BBN, the CIBER-EHD (Centro de Investigacin Biomdica en Red en el rea temtica de Enfermedades hepticas y Digestivas), the firm Janus Developments, the Leibniz University of Hannover and the Helmholtz Centre for Infection Research in Germany.

The use of inclusion bodies as therapeutic agents was patented by UAB and CIBER-BBN (patent code: WO2010131117A1), and licensed to the biotechnology firm Janus Developments, which currently invests in the development of the product.


'/>"/>

Contact: Antoni Villaverde
antoni.villaverde@uab.cat
34-935-813-086
Universitat Autonoma de Barcelona
Source:Eurekalert

Related biology news :

1. Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology
2. Great bustards to be released on Salisbury Plain
3. SNM releases new fact sheet on breast cancer and molecular imaging
4. Loggerhead release to provide vital information to scientific community
5. Global warming predicted to hasten carbon release from peat bogs
6. American Dietetic Association releases 2008 nutrition trends survey
7. UH Manoa researchers release results of statewide survey of snail, slug invasions in Hawaii
8. The International Society for Stem Cell Research releases new guidelines
9. New online report on massive jellyfish swarms released
10. Hypertension and cholesterol medications present in water released into the St. Lawrence River
11. Complete Genomics releases proof-of-concept data for its sequencing technology for the first time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):
(Date:1/11/2017)... ... January 11, 2017 , ... With sepsis claiming ... more than $23.7 billion, healthcare systems are looking to provide better and ... common sepsis-causing pathogens are bacteria and the yeast pathogen Candida, which can lead ...
(Date:1/11/2017)... ... January 11, 2017 , ... IsoPlexis ... response analysis platform to measure the proteomic function of individual cells in patients, ... Research (SBIR) grant from the National Institute on Aging of the National Institutes ...
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology ... Shots and No Surgery for positive back pain relief for WAR members. , This ... worldwide and could be life changing for millions suffering from chronic back pain. , ...
(Date:1/11/2017)... 11, 2017 AnaptysBio, Inc., a clinical-stage ... on unmet medical needs in inflammation, today announced ... chief financial officer.  Mr. Piscitelli will play a ... as overseeing the company,s accounting and SEC reporting ... welcome Dominic to the senior management team at ...
Breaking Biology Technology: